secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2025-03-25T23:59:59+00:00
Accession:  0001372514-25-000014
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora reports 2024 net income $3.6M; two Phase 2 retinal trials approved; cash runway into 2027
--------------------------------------------------------------------------------

- Year-end cash, equivalents, and short-term investments $26.8M; expected runway into 2027.
- Net income $3.6M in 2024 vs net loss $12.5M in 2023; Q4 2024 net loss $4.2M.
- Received approval for KLARITY (Phase 2 KIO-104) and ABACUS-2 (Phase 2 KIO-301) studies.
- Recognized $16M in collaboration revenue from Laboratoires Théa for KIO-301 in 2024.
- Data readouts from both Phase 2 trials expected in 2026; first patient dosing in Q2 2025 for KLARITY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251425000014/0001372514-25-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251425000014/kprx-20250325.htm
  HTML page:      https://secwatch.observer/filing/0001372514-25-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer